Risk of blood clots two-fold for women with polycystic ovary syndrome on combined pill

December 3, 2012 in Medications

Women with polycystic ovary syndrome (PCOS) who are taking combined oral contraceptives have a 2-fold risk of blood clots compared with women without the disorder who take contraceptives, states a study published in CMAJ (Canadian Medical Association Journal).

PCOS affects between 6% and 10% of women of reproductive age with some estimates as high as 15%, making it the most common in this age group. such as hypertension, diabetes, obesity and others are double among women with PCOS compared with women without the disorder. It is usually treated with combined oral contraceptives to regulate menstrual cycles and to help with acne and excessive hair growth associated with the condition. However, combined oral contraceptives are known to increase the risk of cardiovascular events.

Researchers from the US and Canada looked at 87 012 women aged 18 to 46 years in the US, half with PCOS and half as controls, to determine whether women with PCOS taking are at increased risk of venous compared to matched contraceptive users. They excluded women with a history of heart disease, cancer and previous blood clots.

"We found a 2-fold increased risk of venous thromboembolism among women with PCOS taking combined oral contraceptives compared with matched controls," states Steven Bird, lead author and pharmacoepidemiologist with the (FDA) in the United States, with coauthors. "We found a similar increased risk when we expanded the definition of PCOS by including its symptoms and treatment. We also found a 1.5-fold increased relative risk of venous thromboembolism among women with PCOS who were not taking contraceptives compared with matched controls."

"Our findings are consistent with the previously reported 2-fold increase in most of the risk factors for venous thromboembolism among women with PCOS."

"Physicians should consider the increased risk of venous thromboembolism when prescribing contraceptive therapy to women with PCOS," conclude the authors.

More information: www.cmaj.ca/lookup… /cmaj.120677

Journal reference: Canadian Medical Association Journal search and more info website

Provided by Canadian Medical Association Journal search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created May 23, 2013 | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created May 23, 2013 | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Alzheimer's disease, the soft target of the euthanasia debate

(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.